newsfilter
← Latest News
GlobeNewswire·

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a